Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 606-646

  Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^b   Chumakov, Konstantin M ^c   Halsey, Neal A ^d   Hovi, Tapani ^e   Minor, Philip D ^f   Modlin, John F ^g   Patriarca, Peter A ^h   Sutter, Roland W ⁱ   Wright, Peter F ^g   Wassilak, Steven G F ^j   Cochi, Stephen L ^j   Kim, Jong Hoon ^a   Thompson, Kimberly M ^a,k  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h BIOLOGICS CONSULTING GROUP INC   (United States)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Dynamic modeling; Expert judgment; Polio eradication

Indexed keywords

ADDITIONAL DATUM; CENTERS FOR DISEASE CONTROL AND PREVENTIONS; EXPERT ASSESSMENT; EXPERT JUDGMENT; INTERNATIONAL GROUP; KNOWLEDGE SUPPORTS; POLIO ERADICATION; QUANTITATIVE ASSESSMENTS;

DYNAMIC MODELS; PHYSIOLOGY; UNCERTAINTY ANALYSIS; VACCINES;

RESEARCH;

DISEASE CONTROL; DISEASE TRANSMISSION; EXCRETION; IMMUNITY; INFECTIOUS DISEASE; LITERATURE REVIEW; POLICY MAKING; POLIOMYELITIS; RESEARCH WORK; RISK ASSESSMENT; VACCINE; VIRUS;

ARTICLE; DISEASE TRANSMISSION; HUMAN; IMMUNOLOGY; POLIOMYELITIS;

HUMANS; POLIOMYELITIS;

UNITED STATES;

POLIOVIRUS;

EID: 84875951340     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12031     Document Type: Article

References (61)

1. World Health Organization. Global Polio Eradication Initiative-Strategy and work. Available at: http://www.polioeradication.org/Resourcelibrary/Strategyandwork.aspx, Accessed on February 20, 2013.
2. Aylward RB, Sutter RW, Heymann DL. OPV cessation: The final step to a "polio-free" world. Science, 2005; 310(5748):625-626.
3. World Health Organization. Polio Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) Use After Global Polio Eradication. Framework for National Policy Makers in OPV-Using Countries. Geneva, Switzerland, 2005. Report No. WHO/POL/05.02.
4. World Health Assembly. Poliomyelitis: Mechanism for Management of Potential Risks to Eradication (Resolution 61.1). Geneva: World Health Organization, 2008.
5. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-Eradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 2013; 33(4):516-543.
6. Kew OM, Sutter RW, de Gourville E, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 2005; 59:587-635.
7. Sangrujee N, Duintjer Tebbens RJ, Cáceres VM, Thompson KM. Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine, 2003; 5(4):35.
8. Eichner M, Dietz K. Eradication of poliomyelitis: When can one be sure that polio virus transmission has been terminated? American Journal of Epidemiology, 1996; 143(8):816-822.
9. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. American Journal of Epidemiology, 2012; 175(9):936-949.
10. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
11. Fine PEM. Herd immunity: History, theory, practice. Epidemiologic Reviews, 1993; 15(2):265-302.
12. Fox JP, Gelfand HM, LeBlanc DR, Rowan DF. The influence of natural and artificially induced immunity on alimentary infections with polioviruses. American Journal of Public Health, 1958; 48(9):1181-1192.
13. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Pp. 631-686 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines, 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
14. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis, 2008; 28(4):855-876.
15. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
16. Duintjer Tebbens RJ, Pallansch MA, Alexander JP, Jr., Thompson KM. Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine, 2010; 28(26):4312-4327.
17. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
18. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape Journal of Medicine, 2008; 10(8):190.
19. Thompson KM, Duintjer Tebbens RJ. Using system dynamics to develop policies that matter: Global management of poliomyelitis and beyond. System Dynamics Review, 2008; 24(4):433-449.
20. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: Insights and lessons learned through modeling. Risk Analysis, 2006; 26(6):1571-1580.
21. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 2006; 26(6):1541-1556.
22. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet, 2007; 369(9570):1363-1371.
23. Eichner M, Hadeler KP. Deterministic models for the eradication of poliomyelitis: Vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Mathematical Biosciences, 1995; 127(2):149-166.
24. Eichner M, Hadeler KP, Dietz K. Stochastic models for the eradication of poliomyelitis: Minimum population size for polio virus persistence. Pp. 315-327 in Isham V, Medley GF (eds). Models for Infectious Human Diseases: Their Structure and Relation to Data. New York: Cambridge University Press, 1996.
25. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Analysis, 2013; 33(4):544-605.
26. Mallor F, Garcia-Olaverri C, Gomez-Elvira S, Mateo-Collazas P. Expert judgment-based risk assessment using statistical scenario analysis: A case study-running the bulls in Pamplona (Spain). Risk Analysis, 2008; 28(4):1003-1019.
27. Van der Fels-Klerx HJ, Cooke RM, Nauta MN, Goossens LH, Havelaar AH. A structured expert judgment study for a model of campylobacter transmission during broiler-chicken processing. Risk Analysis, 2005; 25(1):109-124.
28. Otway H, von Winterfeldt D. Expert judgment in risk analysis and management: Process, context, and pitfalls. Risk Analysis, 1992; 12(1):83-93.
29. Elmer F, Seifert I, Kreibich H, Thieken AH. A Delphi method expert survey to derive standards for flood damage data collection. Risk Analysis, 2010; 30(1):107-124.
30. Cooke RM. Experts in Uncertainty: Opinion and Subjective Probability in Science. New York: Oxford University Press, 1991.
31. Bernier RH. Some observations on poliomyelitis lameness surveys. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S371-S375.
32. Nathanson N, Kew OM. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology, 2011; 172(11):1213-1229.
33. Plotkin SA, Vidor E. Poliovirus vaccine: Inactivated. In Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines, 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
34. Melnick JL. Poliovirus and other enteroviruses. Pp. 583-663 in Evans AS, Kaslow RA (eds). Viral Infections of Humans: Epidemiology and Control, 4th ed. New York: Plenum Medical, 1997.
35. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press, 1991.
36. Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virologica, 1961; 5:265-273.
37. The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine, 2007; 356(15):1536-1544.
38. Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. American Journal of Hygiene, 1962; 76:173-195.
39. Dowdle WR, van der Avoort HGAM, de Gourville EM, Delpeyroux F, Deshpande JM, Hovi T, Martín J, Pallansch MA, Kew OM, Wolff C. Containment of polioviruses after eradication: Characterizing risk to improve management. Risk Analysis, 2006; 26(6):1449-1469.
40. Glezen PW, McCollough RH, Lamb GA, Chin TDY. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. American Journal of Epidemiology, 1969; 90(2):146-156.
41. Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. American Journal of Epidemiology, 1966; 83(2):224-237.
42. Kogon A, Sigland I, Elveback LR, Fox JP. Oral poliovirus vaccination in middle income families. American Journal of Epidemiology, 1965; 82(1):14-26.
43. Pagano JS, Böttiger M, Bonnevier JO, Gard S. The response and the lack of spread in Swedish school children given an attenuated poliovirus vaccine prepared in human diploid cell strain. American Journal of Hygiene, 1964; 79:74-85.
44. Oostvogel P, van Wijngaarden J, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke H, van Steenis G, van Loon AM. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. Lancet, 1994; 344(8923):665-670.
45. Böttiger M. The elimination of polio in the Scandinavian countries. Public Health Reviews, 1993; 21(1-2):27-33.
46. Lapinleimu K. Elimination of poliomyelitis in Finland. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S457-S460.
47. Böttiger M Polio immunity to killed vaccine: An 18-year follow-up. Vaccine, 1990; 8(5):443-445.
48. Pirez MC, Olivera I, Diabarboure H, Montano A, Baranano R, Badia F, Bonnet MC. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies. Vaccine, 2009; 27(20):2689-2694.
49. Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases, 1993; 168(2):452-454.
50. Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Reviews of Infectious Diseases, 1980; 2:352-369.
51. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 1999; 150(10):1001-1021.
52. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Poliovirus Vaccine Viruses: Implications for the Global Poliomyelitis Eradication Initiative. London: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene, 1998.
53. Estívariz CF, Watkins M, Handoko D, Rusipah R, Deshpande J, Rana BJ, Irawan E, Widhiastuti D, Pallansch MA, Thapa A, Imari S. A large vaccine-derived poliovirus outbreak on Madura Island, Indonesia, 2005. Journal of Infectious Diseases, 2008; 197(3):347-354.
54. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nature Reviews Microbiology, 2007; 5(12):952-958.
55. Minor PD. The molecular biology of poliovaccines. Journal of General Virology, 1992; 73(pt. 12):3065-3077.
56. John TJ, Jain H, Ravishankar K, Amaresh A, Verma H, Deshpande J, Pallansch MA, Singh AP, Sreevatsava M, Burton A, Malankar P, Chatterjee A, Sutter RW. Monovalent type 1 oral poliovirus vaccine among infants in India: Report of two randomized double-blind controlled clinical trials. Vaccine, 2011; 29(34):5793-5801.
57. Plotkin SA, Lebrun A, Koprowski H. Vaccination with the chat strain of type 1 attenuated poliomyelitis virus in Leopoldville. Belgian Congo. 2. Studies of the safety and efficacy of vaccination. Bulletin of the World Health Organization, 1960; 22:215-234.
58. Plotkin SA, Pagano JS, Koprowski H. Vaccination of full-term infants with attenuated polioviruses. Pp. 294-301 in 2nd International Conference on Live Poliomyelitis Vaccines. Washington, DC: Pan American Health Organization, 1960.
59. Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande JM, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: A randomised, double-blind, controlled trial. Lancet, 2010; 376(9753):1682-1688.
60. Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PH, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Reports, 2012; 127(1):23-37.
61. Duintjer Tebbens RJ, Thompson KM, Hunink M, Mazzuchi TM, Lewandowski D, Kurowicka D, Cooke RM. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making, 2008; 28(2):182-200.